Kouris Anargyros, Vavouli Charitomeni, Markantoni Vasiliki, Kontochristopoulos George
J Drugs Dermatol. 2014 Nov;13(11):1315-6.
Palmar hyperhidrosis is a chronic disorder, resistant to conventional treatment. Clinical studies suggest the effectiveness of botulinum toxin A in the treatment of primary palmar hyperhidrosis.
To evaluate the efficacy of botulinum toxin A in the therapy of palmar hyperhidrosis and the frequency of incurred muscle weakness.
Four hundred seventy-four patients with palmar hyperhidrosis were enrolled in the study. The Hyperhidrosis Disease Severity Scale (HDSS) and the Minor-iodine starch test were chosen to assess the disease severity. In addition, a physician's global assessment scale was used to evaluate the effectiveness of the treatment with BTX-A.
There were 312 females and 162 males aged 19-48 (mean 29 years). The improvement following the injection at two weeks and at one, three, six and nine months, as evaluated by physicians, was 82%, 83%, 74%, 48% and 28%, respectively. Two hundred and seventy five patients reported local pain and muscle weakness occurred in 102 patients.
BTX-A led to the reduction of disease severity while transient side effects were reported.
掌部多汗症是一种慢性疾病，对传统治疗有抵抗性。临床研究表明A型肉毒毒素治疗原发性掌部多汗症有效。
评估A型肉毒毒素治疗掌部多汗症的疗效及发生肌肉无力的频率。
474例掌部多汗症患者纳入本研究。采用多汗症疾病严重程度量表（HDSS）和Minor碘淀粉试验评估疾病严重程度。此外，使用医生整体评估量表评估BTX-A治疗的有效性。
共312例女性和162例男性，年龄19 - 48岁（平均29岁）。经医生评估，注射后两周、1个月、3个月、6个月和9个月时的改善率分别为82%、83%、74%、48%和28%。275例患者报告有局部疼痛，102例患者出现肌肉无力。
BTX-A可降低疾病严重程度，但有短暂的副作用报告。
Zotero 插件